The new Access AMH Advanced aims to provide validated cut-offs for the assessment of ovarian reserve and ovarian response as an aid for women undergoing in vitro fertilization (IVF)
Watch world-leading clinical scientists and healthcare professionals online, June 22-23, to discover the latest tools and techniques advancing COVID-19 diagnostic testing, cardiovascular treatments, point-of-care and more
The catheter transforms care delivery by enabling access to structural heart procedures for patients with tricuspid regurgitation and other pathologies
Catch up on topics from A-TEEM spectroscopy and DNA sequencing to advances in in vitro diagnostics, advancing nano-material research with wet-chemical synthesis and biopharmaceutical R&D
Collaboration follows successful acquisition and commercialization of Oxsed, an Oxford University Spin-out, to scale OxLAMP rapid COVID-19 test globally
A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal specimen.
The fast time-to-result includes a pretreatment process to inactivate the virus as a safeguard for laboratory staff handling the samples
New findings pave way to potentially improved assessment of measurable residual disease in AML patients
New service reduces project time from months to weeks for biopharma customers
The Allplex SARS-CoV-2 Master Assay can detect a total of 10 targets including four coronavirus genes
Seegene’s new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 min
The seamless integration of AI into digital pathology workflows aims to improve quality and efficiency of cancer diagnosis
The antigen test is used to detect the nucleocapsid protein antigen in SARS-CoV-2
Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month
The Simplexa™ SARS-CoV-2 Variants Direct assay aims to enable detection of four mutations associated with virus variants without requiring upfront RNA extraction
The availability of an International Standard (IS) for antibodies facilitates the standardization of SARS-CoV-2 serological methods
Simplified design reduces manufacturing time and offers improved functionality to help streamline antibody discovery, cell line development, cell therapy, and synthetic biology workflows
Platform poised to be first CLIA-waived CRISPR-based, point-of-care COVID-19 device with central-lab performance, developed in collaboration with Sherlock Biosciences
Explore topics from live-cell analysis, in situ hybridization, cancer therapeutics, cell imaging, and much more
For a chance to win a $500/£400/450€ Amazon Gift Card, cast your vote for the new products which have made the most difference to clinical diagnostics
In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years
Explore topics from HRIM-MS for enhancing structural characterization to microbial monitoring, in situ hybridization and advances in fragrance profiling
